Covid-19 tablet therapy extremely efficient at stopping hospitalisation, dying

A prominent Thai virologist says the world’s first oral therapy for Covid-19 is highly efficient if taken inside 5 days of signs developing. Dr Yong Poovorawan from the Centre of Excellence in Clinical Virology at Chulalongkorn University made the statement on his Facebook web page yesterday. According to a Bangkok Post report, he was citing analysis published on the health sciences website, medRxiv.
“Molnupiravir is the first oral, direct-acting antiviral proven to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favourable safety and tolerability profile.”
Yong says the Molnupiravir pill, developed by pharmaceutical agency Merck, can reduce the risk of hospitalisation or demise in Covid-19 sufferers. The medication is presently awaiting approval from the US Food and Drug Administration. The Bangkok Post reports that 5 pharmaceutical firms in India have been authorised to manufacture Molnupiravir, which Yong says should make the therapy extra inexpensive.
The cost of Molnupiravir is proving a contentious concern, with one Thai activist filing a grievance in opposition to the Public Health Ministry, the Department of Medical Services, and the Thai Food and Drug Administration. Nimit Tienudom lodged the criticism on October 15, protesting the high cost of the drug, which it’s understood has been set at 23,000 per course of remedy.
Other civil teams have voiced frustration that the Public Health Ministry has thus far solely negotiated with Merck. Jackpot say that whereas this was carried out for the first 200,000 treatment courses, the federal government ought to now shift to negotiating with the Indian manufacturers in order to make future therapy extra reasonably priced.
For more info on Covid-19 Insurance, CLICK HERE..

Leave a Comment